(0.32%) 5 116.17 points
(0.38%) 38 386 points
(0.35%) 15 983 points
(-1.35%) $82.72
(6.34%) $2.05
(0.05%) $2 348.40
(-0.30%) $27.45
(4.12%) $960.10
(-0.21%) $0.933
(-0.37%) $10.98
(-0.54%) $0.796
(1.66%) $93.40
3 days till quarter result
(bmo 2024-05-02)
Expected move: +/- 6.04%
2.83% $ 147.36
@ $146.59
Ausgestellt: 29 Apr 2024 @ 21:04
Rendite: 0.53%
Vorheriges Signal: Apr 29 - 16:32
Vorheriges Signal:
Rendite: -0.54 %
Live Chart Being Loaded With Signals
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference...
Stats | |
---|---|
Tagesvolumen | 417 560 |
Durchschnittsvolumen | 839 403 |
Marktkapitalisierung | 18.63B |
EPS | $0 ( 2024-02-15 ) |
Nächstes Ertragsdatum | ( $-0.750 ) 2024-05-02 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -41.75 |
ATR14 | $4.99 (3.39%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-20 | Fitzgerald Kevin Joseph | Sell | 0 | Common Stock |
2024-03-20 | Fitzgerald Kevin Joseph | Buy | 0 | Common Stock |
2021-02-11 | Fitzgerald Kevin Joseph | Sell | 9 000 | Performance Stock Option 2017 (right to buy) |
2024-03-20 | Fitzgerald Kevin Joseph | Sell | 16 250 | Stock Option (right to buy) |
2024-03-20 | Fitzgerald Kevin Joseph | Sell | 6 667 | Stock Option (right to buy) |
INSIDER POWER |
---|
-6.10 |
Last 99 transactions |
Buy: 237 064 | Sell: 275 392 |
Volumen Korrelation
Alnylam Pharmaceuticals Korrelation
10 Am meisten positiv korreliert | |
---|---|
DSPC | 0.92 |
AZTA | 0.918 |
MAGS | 0.917 |
RMRM | 0.915 |
SLVO | 0.914 |
EIGR | 0.912 |
MMAC | 0.906 |
VWE | 0.905 |
ALVR | 0.903 |
CVAC | 0.903 |
10 Am meisten negativ korreliert | |
---|---|
MYNA | -0.939 |
MLTX | -0.916 |
NRDS | -0.914 |
HYPR | -0.912 |
EBSB | -0.911 |
FLXN | -0.911 |
UPTD | -0.906 |
NRC | -0.903 |
MNTV | -0.901 |
STRL | -0.898 |
Wussten Sie das?
Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).
Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.
Alnylam Pharmaceuticals Korrelation - Währung/Rohstoff
Alnylam Pharmaceuticals Finanzdaten
Annual | 2023 |
Umsatz: | $1.83B |
Bruttogewinn: | $1.52B (83.02 %) |
EPS: | $-3.52 |
FY | 2023 |
Umsatz: | $1.83B |
Bruttogewinn: | $1.52B (83.02 %) |
EPS: | $-3.52 |
FY | 2022 |
Umsatz: | $1.04B |
Bruttogewinn: | $868.60M (83.73 %) |
EPS: | $-9.30 |
FY | 2021 |
Umsatz: | $844.29M |
Bruttogewinn: | $704.14M (83.40 %) |
EPS: | $-7.20 |
Financial Reports:
No articles found.
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Über Live-Signale
Die Live-Signale auf dieser Seite helfen dabei zu bestimmen, wann man NA kaufen oder verkaufen soll. Die Signale haben eine Verzögerung von bis zu 1 Minute; wie bei allen Marktsignalen besteht die Möglichkeit von Fehlern oder Fehleinschätzungen.
Die Live-Handelssignale sind nicht endgültig und getagraph.com übernimmt keine Verantwortung für Maßnahmen, die aufgrund dieser Signale ergriffen werden, wie in den Nutzungsbedingungen beschrieben. Die Signale basieren auf einer breiten Palette von technischen Analyseindikatoren.